PDF Summary:Estrogen Matters, by Avrum Bluming and Carol Tavris

For decades, hormone replacement therapy has been viewed with suspicion, largely due to concerns about breast cancer and cardiovascular risks. In Estrogen Matters, Avrum Bluming and Carol Tavris challenge this conventional wisdom by reexamining the research on estrogen therapy for menopausal women.

The authors argue that estrogen therapy offers significant benefits, including relief from menopausal symptoms, protection against heart disease and osteoporosis, and potential prevention of cognitive decline. They contend that the widely publicized risks of hormone therapy—particularly regarding breast cancer and heart disease—have been misinterpreted or overstated. By analyzing studies and clinical evidence, Bluming and Tavris present a case for reconsidering estrogen therapy as a safe and effective treatment option for postmenopausal women, particularly when started within ten years of menopause.

(continued)...

(Shortform note: Vasomotor symptoms are sudden, recurring episodes of heat, flushing, and sweating. They occur because menopause-related hormonal shifts destabilize the brain’s internal temperature-control system. The hypothalamus, which regulates body temperature, becomes more sensitive to small changes in temperature. This causes the body to overreact to minor temperature fluctuations, leading to hot flashes and night sweats. The hypothalamus is also involved in regulating sleep, mood, and appetite, which explains why menopause can affect these areas.)

The main alternatives to HRT include plant-based and natural remedies, like nonprescription Chinese medicinal plants, Actaea racemosa, Panax ginseng, St. John's wort, and ginkgo biloba. However, research consistently shows they don't reduce menopausal symptoms beyond a placebo effect.

(Shortform note: This statement is likely inaccurate. For example, researchers found that St. John's wort produced greater improvements in depressive symptoms than a placebo. This suggests that the authors' claim that research consistently shows these remedies don't work may be an overgeneralization. While some studies may not find significant effects, others do, indicating that the efficacy of these treatments may vary depending on the specific condition, dosage, and individual response.)

Maintaining Good Health and Living Longer

Bluming and Tavris argue that treatment with estrogen might help prevent diseases and extend life. It could lower the chances of developing Alzheimer’s, fractures of the hip, colorectal cancer, and cardiac disease, and increase life expectancy by up to three years for postmenopausal women.

(Shortform note: While estrogen treatment may extend life for many postmenopausal women, it can have the opposite effect for those with certain medical conditions. For example, medical researchers warn that estrogen can trigger life-threatening attacks in women with acute hepatic porphyria, a rare genetic disorder affecting the liver. This condition causes the body to produce excess porphyrins, which can lead to severe abdominal pain, neurological symptoms, and even death.)

Reassessing the Dangers: From WHI Controversy to Current Understanding

Let’s challenge the association of estrogen with breast cancer and reevaluate the risk of cardiovascular disease, cognitive decline, and more.

Challenging the Estrogen-Breast Cancer Link

Bluming and Tavris argue that studies indicate hormone replacement therapy doesn't raise the likelihood of cancer coming back. A 1994 review of research found little clinical evidence to support the concern that hormone therapy might activate dormant tumor cells. A 2000 review found that estrogen didn’t negatively affect breast cancer treatments, even at higher concentrations than in standard HRT prescriptions. The review concluded that estrogen neither worsened the outlook, hastened the progression of the disease, nor lessened survival chances or complicated breast cancer management.

Additionally, a 2002 review found no heightened recurrence risk in breast cancer survivors using HRT compared to those who didn't. The review also indicated that breast cancer survivors on estrogen had a considerably lower mortality rate of 3% compared to the 11.4% rate of those who weren't.

Hormone Therapy and Breast Cancer Recurrence

Contrary to the authors’ claim, oncology researchers argue that hormone replacement therapy does increase the risk of breast cancer recurrence. In a clinical study, medical researchers randomly assigned breast cancer survivors to two groups: one group received hormone therapy, while the other group did not. The results showed that the group receiving hormone therapy had a higher rate of subsequent breast cancer events compared to the group that did not receive hormone therapy. This suggests that hormone therapy may increase the risk of breast cancer recurrence in survivors.

Re-Evaluating Cardiovascular, Cognitive & Other Risks

Bluming and Tavris contend that estrogen may help avert cardiovascular conditions and strokes. It reduces vasoconstrictors, which are substances that cause the arteries to narrow, while boosting vasodilators, which help widen them. This leads to enhanced cerebral circulation and blocks inflammation-inducing compounds involved in early atherosclerosis.

Two randomized controlled trials showed how estrogen benefits heart disease. One found that estrogen treatment alone or with HRT for younger postmenopausal women resulted in a 30% drop in myocardial infarctions and cardiac fatalities. Another found that acute cardiac events decreased by 50% among women on estrogen or HRT.

According to the Women’s Health Initiative, estrogen didn’t raise stroke risk in younger women entering menopause who were in good vascular health. However, women older than sixty who were obese, had high blood pressure, and smoked had an elevated risk, and thus likely already had some level of atherosclerosis.

Updated Guidelines on Estrogen Therapy and Cardiovascular Health

Since the publication of Estrogen Matters, new research has led to updated guidelines on estrogen therapy and cardiovascular health. Faubion et al. (2023) emphasize the importance of individualized risk assessment, noting that estrogen therapy may benefit younger postmenopausal women but could pose risks for older women with existing cardiovascular conditions. The authors also highlight that hormone therapy should not be used for the primary prevention of cardiovascular disease or stroke, and that decisions about initiating or continuing systemic hormone therapy should be individualized and periodically reevaluated, taking into account a woman’s age, time since menopause, cardiovascular risk profile, and personal preferences regarding benefits and risks.

Now, we’ll discuss how estrogen influences neurological risk.

Neurological Risk Reassessment

Bluming and Tavris suggest that estrogen may help preserve cognitive function and lower the chances of Alzheimer's in postmenopausal women. They explain that estrogen encourages nerve cell growth, regenerates axons, and reduces the nerve-cell death that occurs with Alzheimer’s. It makes brain cells more sensitive to nerve growth factor and lessens the production of Alzheimer's-related substances like beta amyloid and tau protein. Estrogen also decreases vasoconstrictor levels, raises vasodilator levels, and increases cerebral blood flow. Additionally, it boosts neurons' capacity to withstand various physiological harms, including illnesses and head trauma.

(Shortform note: Roberta Diaz Brinton, a neuroscientist and director of the Center for Innovation in Brain Science at the University of Arizona, has conducted extensive research on the effects of estrogen on the brain. She explains that estrogen binds to specific receptors in brain cells, which then influence the activity of genes within the cell nucleus and mitochondria. This process alters how neurons produce and manage energy, especially during times of biological stress. Estrogen's ability to regulate these cellular processes helps maintain brain function and protect against age-related cognitive decline.)

The WHI found no increased likelihood of dementia or cognitive decline for women solely on estrogen. The risk slightly increased for those undergoing HRT if they already had cognitive issues or began hormone therapy long after menopause, after age 75. It appears that there's a timeframe during which estrogen can provide lasting cognitive benefits—the ten years after menopause begins. Starting estrogen after age 60 or long after menopause begins could be ineffective and might carry risks.

Does the WHI Study Apply to Vaginal Estrogen?

The WHI study focused on systemic estrogen, which is absorbed into the bloodstream and affects the entire body. However, medical experts note that the WHI study didn’t include women who only used low-dose vaginal estrogen, which is absorbed locally and has minimal systemic effects. Some menopause experts argue that the WHI study’s findings on dementia risk may not apply to women who use only low-dose vaginal estrogen. They point out that the WHI study didn’t include women who used only low-dose vaginal estrogen, so it’s unclear whether the same age and timing recommendations apply. A clinical position statement on genitourinary syndrome of menopause (GSM) notes that low-dose vaginal estrogen is considered safe and effective for treating GSM symptoms, even in women over 60.